News SCHOTT Pharmaceutical Systems

Please insert search term:
Ypsomed collaborates with SCHOTT and Lonza to develop a comprehensive solution for combination products based on patch injectors
Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT, one of the leading suppliers of pharmaceutical primary packaging, and Lonza, a leading global partner of the pharmaceutical and biotechnology industry for the development, manufacturing and testing of pharmaceuticals. In a joint effort, the three companies are developing a comprehensive solution for wearable patch injectors for the subcutaneous self-injection of large volumes of liquid formulations. This solution should enable pharmaceutical companies to quickly bring biopharmaceuticals in a patch injector into the clinical trial stage and to the market. For patients, the solution reduces the number of hospital visits required for treatment. More
SCHOTT AG and Credence MedSystems form a strategic Collaboration Agreement to make Syringe Injections safer for the benefit of Patients worldwide
Credence MedSystems and SCHOTT AG have formed a collaboration for the application of Credence Companion® technology with SCHOTT’s pre-fillable syriQ® glass and SCHOTT TOPPAC® polymer syringe systems. The two companies will work together to integrate the technologies and provide the pharmaceutical industry with an innovative and differentiated offering for the delivery of injectable medications via prefilled syringes. More
Three out of every four COVID-19 vaccine projects across the globe rely on SCHOTT vials
In 2019, SCHOTT announced a $1 billion investment in its pharmaceutical packaging business to expand capacity by more than 50 percent. Now, SCHOTT has achieved a milestone, delivering vials to three out of every four COVID-19 vaccine projects undergoing phase I, II, and III testing (Source: Global Data). Already, the company has delivered millions of glass vials to SARS-CoV-2 programs including partners of Operation Warp Speed in the U.S. More
SCHOTT delivers pharma vials to package 2 billion doses of COVID-19 vaccines
SCHOTT supports the world’s fight against COVID-19 with vials capable of holding up to 2 billion vaccination doses. The glassmaker and pharma packaging specialist has reached agreements with leading pharmaceutical companies, including partners of ‘Operation Warp Speed’ – the US government initiative to serve local vaccine production needs. The agreements become effective immediately and first vials are being delivered to companies in North America, Europe and Asia. SCHOTT is ideally positioned to meet the challenging demand situation, as it has been maintaining a global and already validated production network for decades. Even before the expansion, the company already produced more than 11 billion pharma containers for life-saving drugs per annum. More
Leading pharma packaging companies commit to supply for Covid-19 fight
Stevanato Group, SCHOTT, and Gerresheimer confirm the readiness to support future Covid-19 Vaccine with pharmaceutical containers More
SCHOTT Smart Containers: Entering a new era in digitized pharma manufacturing
In light of the growing need for pharmaceutical packaging innovations and digitalization, international technology group SCHOTT is introducing Smart Containers. The concept enables industry 4.0 for pharma manufacturers to unlock the power of machine vision and big data analytics on pharmaceutical filling lines. Each SCHOTT Smart Container is laser-marked with a unique identifier to create unprecedented traceability throughout the manufacturing process. The technology can be used to improve reject management and line clearance. Other applications include reducing the risk of mix-up, optimizing lyophilization processes, and supporting container-based targeted recalls. More
SCHOTT extends syriQ BioPure® syringe format to enable optimized administration
The new 2.25mL long syringe was developed for highly viscous biologics, which are administered by use of an autoinjector.

syriQ BioPure® syringes are specifically designed to keep sensitive biologic drugs stable over their shelf life while easing the administration process for patients. The portfolio now includes a new 2.25mL syringe format, which supports both the drug’s and patient’s needs when it comes to administering highly viscous biologics by autoinjector. The new container format will be introduced at Pharmapack trade show in Paris, February 5-6, where SCHOTT is presenting its full range of pharmaceutical containers at booth D60.
SCHOTT investing to triple production of pharmaceutical polymer containers
Global demand for specialized drug delivery devices driving new investments worth several hundred million euros at existing facility in Müllheim, Germany.

Global pharmaceutical systems specialist SCHOTT is again increasing its production capacity for ready-to-use polymer syringes and individualized containers. To meet the high market demand, the company will invest a nine-figure sum to add a new production plant at its existing site in Müllheim, Germany. Construction is scheduled for completion by the end of 2021 with a significant increase in production expected to begin in 2022. The investment also includes a pilot center, allowing for rapid prototyping of packaging innovations.
SCHOTT teams up with SINCAD to ensure the highest quality pharmaceutical packaging
Pharma Packaging division signs exclusive cooperation and development agreement with French engineering company that specializes in developing and manufacturing vision control systems

The international technology group SCHOTT and the French engineering firm SINCAD have signed an exclusive cooperation and development agreement aimed at strengthening SCHOTT’s expertise in the field of camera inspection systems. The agreement includes the assurance that SINCAD will distribute its highly advanced camera systems exclusively to SCHOTT and not offer them to any other supplier in the pharmaceutical industry in the future.
SCHOTT TOPPAC® cosmetic syringes: Injecting beauty made easy
International technology group SCHOTT is introducing SCHOTT TOPPAC® cosmetic, a new COC (cyclic olefin copolymer) polymer syringe specifically designed for cosmetic and medical applications involving hyaluronic acid. Thanks to a reduced needle pop-off risk, improved dose accuracy and high break resistance, the syringes are especially suitable for highly viscous drugs. The new polymer syringes will become available in February 2019 and will be displayed at IMCAS World Congress in Paris, Jan. 31 to Feb. 2, at TSK Laboratory’s booth #46. More
SCHOTT completes portfolio of ready-to-use adaptiQ® vials with 15R to 30R ISO formats
As the first supplier of nested ready-to-use vials, SCHOTT has expanded its portfolio by large-size ISO formats of 15R, 20R, 25R and 30R vials commercially available for human use (FHU). The vials, which are delivered pre-sterilized in a tub and nest configuration, are manufactured at the company’s production site in USA and are ready to order. More
SCHOTT to invest 300 million euros in pharmaceutical packaging business
Group to build new production facilities in Germany and China and expand capacity in India and Switzerland More
SCHOTT increases production capacity for polymer syringes by 50 percent
Additional multimillion-euro investment at Swiss competence center More
Perfecting surfaces: SCHOTT enhances production setup for coated vials, doubles capacity
Quartz coatings offer utmost protection for highly sensitive drugs / Hydrophobic layers make lyophilization more efficient / New production setup designed to minimize glass-to-glass contact and particle load More
Exhibitions & Events
Exhibition CPhI Worldwide, Milano, Italy, 08-31 to 09-02-2021
SCHOTT uses Cookies on this Website to enhance the user experience and provide the best possible Service. By continuing to browse the Website, you consent to our use of Cookies.